Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 14, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 22, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray , MD, FAAP to its Board of Directors.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release Continued Progress in Ongoing MIRASOL, IMGN632, and IMGC936
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 15, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on June 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--May 20, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
View HTML
Toggle Summary ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
Results to be Presented in an Oral Session at 2021 ASCO Annual Meeting Combination Demonstrates Strong Anti-Tumor Activity in Patients with High FRα Expression, with a Confirmed Overall Response Rate of 64%, Median Duration of Response of 11.8 Months and Median Progression-Free Survival of 10.6
View HTML